Nekonal Oncology is an early stage biotechnology company focused on the development of first-in-class antibodies against a novel T cell based target. These treatments could be used as a monotherapy or combination therapy for both solid and hematological malignancies. Currently, the company is characterizing its candidate antibodies and is aiming to select leads for IND enabling work.
Portage shareholders own 25% of Nekonal Oncology. Portage also serves as Chief Executive Officer, Head of Research, provides project management and financial support and holds the Chairman and executive member seats on the Board of Directors.